XNCR Stock Analysis: Buy, Sell, or Hold?
XNCR - Xencor, Inc.
$12.78
0.58 (4.75%)
▲
5d:
+8.03%
30d:
+15.55%
90d:
+10.27%
BUY
MODERATE Confidence
Analysis Updated: Jun 17, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Get Alerted When XNCR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: XNCR shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: XNCR shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: XNCR is currently trading at $12.78, which is considered extended relative to its 30-day fair value range of $11.25 to $12.32.
Technical Outlook: Technically, XNCR is in a downtrend. Immediate support is located at $11.20, while resistance sits at $13.26. The stock is showing strong short-term momentum, up 4.8% recently.
Market Sentiment: XNCR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $28.50 (+123.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, XNCR is in a downtrend. Immediate support is located at $11.20, while resistance sits at $13.26. The stock is showing strong short-term momentum, up 4.8% recently.
Market Sentiment: XNCR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $28.50 (+123.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$11.25 -
$12.32
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
68.4%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.8%)
- BULLISH: Trading 123.0% below Wall St target ($28.50)
Trading Range Analysis
30-Day Trading Range
$11.25 -
$12.32
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$11.20
Resistance Level
$13.26
Current Trend
Downtrend
Technical data as of
Jun 17, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.59
Wall Street Target
$28.50
(+123.0%)
Revenue Growth (YoY)
-86.2%
Profit Margin
-177.1%
Share & Embed Analysis
Last updated: June 17, 2026 9:28 PM ET
Data refreshes hourly during market hours. Next update: 10:28 PM
Data refreshes hourly during market hours. Next update: 10:28 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XNCR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
9
Sells
Net
INSIDERS SELLING
Recent Transactions
Bassil I Dahiyat
SELL
6606 shares
2026-03-06
Celia Eckert
SELL
1767 shares
2026-03-06
John R Desjarlais
SELL
2502 shares
2026-03-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 62 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$102 | 58 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 60 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 59 HOLD |
